$55 billion pharma merger could fall victim to new Obama tax rules

HONG KONG (CNNMoney)

Chicago-based AbbVie said Tuesday that its board of directors is reconsidering its recommendation that shareholders adopt the merger with Shire.

The company's board will meet Oct. 20 to examine the potential financial impact of new regulations announced last month by the U.S. Treasury.

Related: 7 things you absolutely must know about corporate taxes

The merger agreement, announced in July, would have seen AbbVie cut its effective tax rate to about 13% in 2016 from 26%.

A U.S. company can't simply relocate to nations with lower tax rates to avoid U.S. corporate taxes. To get the lower foreign tax rate, it must use a process known as "inversion," in which a merger leads to a foreign partner owning more than 20% of the stock in the combined company.

Inversions have been all the rage lately, with companies including Burger King (BKW) seeking to execute the maneuver.

The Treasury's "first, targeted steps" are designed to make inversions less attractive. The rules target loopholes, including one tactic to move U.S. earnings abroad by making a loan to its foreign parent company in efforts to avoid taxes. Under the new regulations, those loans will be treated as U.S. property and will be taxable in many instances.

Related: More companies bail on the U.S. for lower taxes

Critics say the real problem is the corporate tax code, which hasn't kept pace with the transformation of global business over the past few decades.

Related: Burger King buying Tim Hortons

Related: 7 companies that keep more than $50 billion offshore

First Published: October 15, 2014: 12:17 AM ET

Anda sedang membaca artikel tentang

$55 billion pharma merger could fall victim to new Obama tax rules

Dengan url

http://bugarasakti.blogspot.com/2014/10/55-billion-pharma-merger-could-fall.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

$55 billion pharma merger could fall victim to new Obama tax rules

namun jangan lupa untuk meletakkan link

$55 billion pharma merger could fall victim to new Obama tax rules

sebagai sumbernya